Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Peanutbudderon Jan 05, 2018 4:57pm

132 Views

Post# 27293861

RE:RE:RE:monday .30s

tell me somewhere you can find 2 patents.... SUCCESSFUL TRIALS, with huge reduction in patients getting stage 4... HUGE. About to head into Phase 3 with a world class team from Isreal.... in a market that's is one of the most BULL in HISTORY. With all do respect I think your prediction of 30's won't happen... good luck to you. You mentioned you owned Kaly... a substantial amount, how come you bought in already if you think 30s are on the way?

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!